Pittsburgh Penguins defenseman Caleb Jones has received a 20-game suspension after violating the terms of the NHL/NHLPA Performance Enhancing Substances Program. The league announced the disciplinary action on February 4, 2026. This suspension is in accordance with the jointly agreed-upon guidelines set forth by the National Hockey League and the NHL Players’ Association, which aim to uphold the integrity of the sport by deterring the use of performance-enhancing substances.
Jones, 28, joined the Penguins before the 2025–26 season. Prior to signing with Pittsburgh, he played for several other NHL teams, including the Edmonton Oilers and the Chicago Blackhawks. Known for his mobility and puck-moving ability, Jones had been serving as a depth option on Pittsburgh’s blue line this season.
The league’s announcement did not specify the substance involved. Under the terms of the NHL/NHLPA program, players who test positive for performance-enhancing substances are automatically subject to suspension without pay. The substance and details of the specific violation are generally not disclosed under current program guidelines, which also include provisions for evaluation, treatment, and follow-up testing.
The suspension will take effect immediately, and Jones will be eligible to return to the Penguins’ lineup once the 20-game period concludes. In the meantime, the team will need to adjust its defensive rotations in his absence. The Penguins have not yet issued a public statement regarding the suspension.
This development adds to the challenges Pittsburgh faces as it competes for a playoff position in a competitive Eastern Conference. The team’s defensive corps has already seen several changes this season, and losing a roster player for an extended period is likely to impact its depth and strategic approach. Any further updates regarding Jones or changes to the team’s roster will be closely monitored as the season progresses.
